(Q3)Feb 28, 2023 | (Q2)Nov 30, 2022 | (Q1)Aug 31, 2022 | (Q3)Feb 28, 2022 | (Q2)Nov 30, 2021 | (Q1)Aug 31, 2021 | (FY)May 31, 2021 | (Q4)May 31, 2021 | (Q3)Feb 28, 2021 | (Q2)Nov 30, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 57.87%-943.65K | -531.45%-2.01M | -67.43%-757.74K | -440.82%-2.24M | 11.47%-318.48K | -40.59%-452.58K | -7.77%-1.6M | -275.08%-500.08K | 40.65%-414.12K | -359.73K |
Net income from continuing operations | -35.63%-2.38M | -140.00%-2.58M | -111.55%-2.31M | -176.17%-1.76M | -38.21%-1.08M | -73.95%-1.09M | 60.19%-3.28M | 55.63%-1.24M | 29.84%-635.85K | ---779.14K |
Operating gains losses | --0 | ---64.79K | --31.29K | ---- | ---- | ---- | --143.49K | --158.89K | --0 | --0 |
Depreciation and amortization | 55.10%535.77K | 235.91%536.06K | 203.88%498.03K | 119.16%345.44K | 1.25%159.59K | 4.98%163.89K | 86.90%644.57K | 0.44%173.21K | 5.43%157.62K | --157.62K |
Asset impairment expenditure | ---1.38K | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---- | ---- |
Remuneration paid in stock | 46.48%257.66K | -45.05%105.43K | -65.38%122.52K | 50.26%175.9K | 20.70%191.85K | 61.79%353.86K | -66.08%946.44K | -80.95%451.71K | -12.97%117.06K | --158.95K |
Other non cashItems | 9.82%37.78K | 484.27%122.37K | 410.36%67.47K | 83.69%34.41K | -30.19%20.94K | 26.13%13.22K | -97.01%92.99K | 540.39%33.77K | 116.08%18.73K | --30K |
Change In working capital | 154.13%564.51K | -122.39%-86.43K | 674.09%830.72K | -1,354.77%-1.04M | 430.00%385.96K | 265.85%107.32K | -127.97%-144.13K | -115.37%-80.56K | -274.85%-71.69K | --72.82K |
-Change in receivables | 28.28%15.31K | -181.10%-101.93K | 736.15%557.03K | 112.79%11.94K | 1,790.51%125.68K | -69.37%66.62K | -77.60%67.24K | -116.70%-63.55K | 2.87%-93.34K | --6.65K |
-Change in inventory | --0 | 196.26%57.42K | -268.09%-27.45K | ---51.52K | ---59.65K | --16.33K | ---16.33K | ---16.33K | ---- | ---- |
-Change in prepaid assets | 121.38%138.33K | -310.82%-73.53K | 3,067.12%214.89K | -1,714.04%-646.94K | 42.09%-17.9K | -73.24%6.79K | -305.27%-114.12K | -158.91%-72.9K | ---35.66K | ---30.91K |
-Change in payables and accrued expense | 203.05%367.19K | -90.64%31.62K | 390.69%86.26K | -5,153.02%-356.34K | 247.98%337.83K | 106.55%17.58K | -120.51%-41.9K | -7.70%122.49K | -94.86%7.05K | --97.08K |
-Change in other working capital | ---- | ---- | ---- | ---- | ---- | ---- | -200.00%-39.02K | ---50.27K | --50.27K | --0 |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 55.92%-987.33K | -517.73%-1.97M | -67.43%-757.74K | -440.82%-2.24M | 11.47%-318.48K | -40.59%-452.58K | -7.77%-1.6M | -275.08%-500.08K | 40.65%-414.12K | ---359.73K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -65.51%5.4K | 205.43%116.95K | 84.64%-90.91K | 209.66%15.66K | -110.92K | -804.62%-591.99K | -104.59%-79.72K | 0 | 83.53%-14.28K | 0 |
Net PPE purchase and sale | 109.46%7.38K | 33.23%-74.06K | 41.74%-163.56K | -446.19%-78.01K | ---110.92K | -329.00%-280.74K | 85.64%-79.72K | --0 | 83.53%-14.28K | --0 |
Net business purchase and sale | --0 | --0 | --0 | --0 | --0 | ---311.25K | ---- | ---- | --0 | ---- |
Net investment purchase and sale | 99.12%-1.98K | ---2.63K | ---5.13K | ---225.19K | --0 | --0 | ---- | ---- | ---- | ---- |
Net other investing changes | --0 | --193.63K | --77.78K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -65.51%5.4K | 205.43%116.95K | 84.64%-90.91K | 209.66%15.66K | ---110.92K | -804.62%-591.99K | -104.59%-79.72K | --0 | 83.53%-14.28K | --0 |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 144.75%275.67K | -83.92%1.13M | 1,023.69%1.29M | -279.64%-616.01K | 38,272.42%7.02M | -266.36%-139.2K | 311.30%2.35M | 163.94%1.91M | -52.66%342.92K | 18.3K |
Net issuance payments of debt | 44.13%-441.72K | -930.81%-343.27K | -106.79%-391.18K | -1,889.99%-790.62K | 157.50%41.32K | -423.65%-189.17K | 28.50%-275.23K | -96.42%-127.53K | 84.35%-39.73K | ---71.85K |
Net common stock issuance | 73.43%667.39K | -78.34%1.47M | 35,086.66%1.73M | -18.58%384.83K | 4,513,134.67%6.77M | -95.89%4.93K | 174.57%2.63M | 113.57%2.03M | --472.65K | --150 |
Net other financing activities | ---- | --6K | -224.32%-56K | --0 | --0 | --45.05K | ---- | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 144.75%275.67K | -83.92%1.13M | 1,023.69%1.29M | -279.64%-616.01K | 38,272.42%7.02M | -266.36%-139.2K | 311.30%2.35M | 163.94%1.91M | -52.66%342.92K | --18.3K |
Net cash flow | ||||||||||
Beginning cash position | -88.05%836.82K | 269.79%1.57M | -29.48%1.13M | 2,269.50%7M | -33.03%424.81K | 71.34%1.61M | 784.06%938.66K | -86.15%209.71K | -81.22%295.55K | --634.33K |
Current changes in cash | 75.13%-706.26K | -110.95%-721.59K | 136.93%437.11K | -3,222.37%-2.84M | 2,030.67%6.59M | -289.82%-1.18M | -18.23%675.95K | 342.15%1.41M | -42.23%-85.48K | ---341.44K |
Effect of exchange rate changes | -140.55%-6.03K | 9.52%-12.53K | -240.85%-331 | 4,278.09%14.87K | -621.58%-13.85K | 135.23%235 | -207.91%-6.26K | -235.69%-7.9K | ---356 | --2.66K |
End cash Position | -97.02%124.52K | -88.05%836.82K | 269.79%1.57M | 1,892.20%4.18M | 2,269.50%7M | -33.03%424.81K | 71.34%1.61M | 71.34%1.61M | -86.15%209.71K | --295.55K |
Free cash from | 58.14%-979.95K | -375.42%-2.04M | -25.63%-921.3K | -446.49%-2.34M | -19.37%-429.4K | -89.32%-733.32K | 17.70%-1.68M | -555.05%-500.08K | 45.39%-428.4K | ---359.73K |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.